Arcutis Biotherapeutics, Inc. (ARQT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ARQT SEC filings page.
Arcutis Biotherapeutics, Inc. (ARQT) reported $464.0M in revenue over the twelve months to Jun 30, 2026, up 76.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Commercial scale is converting a high-margin launch into near-break-even operations while working capital absorbs more balance-sheet capacity.
Revenue more than doubled in FY2025 while gross margin held at90.2% , pointing to scale absorption rather than a margin reset. Operating cash flow of-$5.6M nearly matched free cash flow of-$6.3M and was less negative than net income, indicating reported losses overstated near-term cash consumption.
Gross margin remained about
Debt-to-equity fell to 0.6x in FY2025 from 0.7x, reducing leverage even as the company expanded. The current ratio declined to 3.2x while accounts receivable reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Arcutis Biotherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Arcutis Biotherapeutics, Inc. has an operating margin of -3.3%, meaning the company loses $3 on every $100 of revenue. This results in a profitability score of 9/100. This is up from -65.3% the prior year.
Arcutis Biotherapeutics, Inc.'s revenue surged 91.3% year-over-year to $376.1M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
Arcutis Biotherapeutics, Inc. has a moderate D/E ratio of 0.57. This balance of debt and equity financing earns a leverage score of 58/100.
With a current ratio of 3.17, Arcutis Biotherapeutics, Inc. holds $3.17 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.
Arcutis Biotherapeutics, Inc.'s operations used $5.6M of cash, and capex of $686K added to the outflow, for a free cash flow shortfall of $6.3M. This results in a cash flow score of 3/100.
Arcutis Biotherapeutics, Inc. posts a -8.5% return on equity (ROE), meaning it loses $9 for every $100 of shareholders' equity. This results in a returns score of 22/100. This is up from -88.9% the prior year.
Arcutis Biotherapeutics, Inc. scores 5.27, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.0B) relative to total liabilities ($243.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Arcutis Biotherapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Arcutis Biotherapeutics, Inc. reported a net loss of $16.1M while operations used $5.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Arcutis Biotherapeutics, Inc. reported an operating loss of $12.2M against $12.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Arcutis Biotherapeutics, Inc. generated $129.9M in revenue in Q2 2026. This represents an increase of 59.3% from the same quarter a year earlier. Against the prior quarter it is up 23.2%.
Arcutis Biotherapeutics, Inc. reported $15.0M in net income in Q2 2026. This represents an increase of 194.5% from the same quarter a year earlier. Against the prior quarter it is up 232.9%.
Arcutis Biotherapeutics, Inc. earned $0.11 per diluted share (EPS) in Q2 2026. This represents an increase of 184.6% from the same quarter a year earlier. Against the prior quarter it is up 222.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
Arcutis Biotherapeutics, Inc. generated $12.5M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 4973.6% from the same quarter a year earlier. Against the prior quarter it is up 457.4%.
Arcutis Biotherapeutics, Inc. held $34.1M in cash against $102.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Arcutis Biotherapeutics, Inc.'s gross margin was 91.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.
Arcutis Biotherapeutics, Inc.'s operating margin was 12.7% in Q2 2026, reflecting core business profitability. This is up 30.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 21.3 percentage points.
Arcutis Biotherapeutics, Inc.'s net profit margin was 11.6% in Q2 2026, showing the share of revenue converted to profit. This is up 31.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.3 percentage points.
Arcutis Biotherapeutics, Inc.'s ROE was 6.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 18.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.8 percentage points.
Capital Allocation
Arcutis Biotherapeutics, Inc. invested $20.4M in research and development in Q2 2026. This represents an increase of 4.6% from the same quarter a year earlier. Against the prior quarter it is down 33.5%.
Arcutis Biotherapeutics, Inc. invested $158K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 102.6% from the same quarter a year earlier.
Not reported for Q2 2026.
ARQT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $129.9M+59.3% | $105.4M+60.1% | $129.5M+81.5% | $99.2M+121.7% | $81.5M+164.1% | $65.8M+32.8% | $71.4M+427.6% | $44.8M+17.4% |
| Cost of Revenue | $10.9M+46.0% | $9.8M+10.8% | $11.7M+69.3% | $8.7M+57.8% | $7.5M+116.3% | $8.8M+171.2% | $6.9M+207.4% | $5.5M+365.6% |
| Gross Profit | $118.9M+60.7% | $95.6M+67.7% | $117.8M+82.8% | $90.5M+130.6% | $74.0M+170.2% | $57.0M+23.1% | $64.5M+471.4% | $39.3M+6.3% |
| R&D Expenses | $20.4M+4.6% | $30.6M+74.6% | $20.5M+41.2% | $19.6M+0.5% | $19.5M+0.8% | $17.5M-24.2% | $14.5M-39.1% | $19.5M-25.7% |
| SG&A Expenses | $82.1M+18.7% | $74.1M+15.7% | $79.0M+37.1% | $62.4M+6.1% | $69.2M+18.9% | $64.0M+16.8% | $57.6M+18.4% | $58.8M+23.6% |
| Operating Income | $16.4M+212.4% | -$9.1M+62.9% | $18.4M+340.9% | $8.5M+121.8% | -$14.6M+70.8% | -$24.5M+22.4% | -$7.6M+87.5% | -$39.1M-5.9% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | -$21.4M+31.6% | -$7.2M+97.1% | -$37.6M-124.9% |
| Interest Expense | $3.4M+12.4% | $4.4M+46.5% | $3.0M-45.9% | $3.1M-53.8% | $3.0M-59.5% | $3.0M-60.1% | $5.6M-28.5% | $6.7M-12.0% |
| Income Tax | $136K-60.2% | $93K-66.7% | $470K+45.5% | $80K | $342K | $279K-13.9% | $323K+258.9% | $0-100.0% |
| Net Income | $15.0M+194.5% | -$11.3M+54.9% | $17.4M+261.2% | $7.4M+117.8% | -$15.9M+69.6% | -$25.1M+29.2% | -$10.8M+83.7% | -$41.5M+7.2% |
| EPS (Basic) | $0.11+184.6% | -$0.09+55.0% | $0.13+262.5% | $0.06+118.2% | -$0.13+69.0% | -$0.20+37.5% | -$0.08+86.4% | -$0.33+54.8% |
| EPS (Diluted) | $0.11+184.6% | -$0.09+55.0% | $0.13+262.5% | $0.06+118.2% | -$0.13+69.0% | -$0.20+37.5% | -$0.08+86.4% | -$0.33 |
| Diluted Shares (Avg) | 136M+7.0% | 129,365+2.6% | N/A | 133M+6.9% | 127M+2.8% | 126,037-99.9% | N/A | 124M |
ARQT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $488.5M+38.6% | $460.0M+33.7% | $433.0M+24.1% | $371.0M-15.2% | $352.4M-20.8% | $344.1M-28.1% | $348.9M+2.2% | $437.4M+49.3% |
| Current Assets | $467.7M+40.5% | $438.1M+35.3% | $411.2M+22.5% | $349.2M-17.6% | $332.8M-23.4% | $323.7M-30.8% | $335.8M+1.6% | $423.7M+50.5% |
| Cash & Equivalents | $34.1M-53.1% | $34.8M-34.5% | $42.9M-39.9% | $47.1M-65.1% | $72.7M-13.7% | $53.1M-72.1% | $71.3M-19.3% | $134.9M+25.5% |
| Short-Term Investments | $204.4M+73.1% | $189.2M+30.5% | $178.1M+13.7% | $143.9M-26.4% | $118.1M-57.5% | $145.0M-32.2% | $156.6M-14.6% | $195.7M+63.6% |
| Inventory | $38.9M+138.2% | $37.4M+125.1% | $22.6M+55.8% | $22.4M+60.0% | $16.3M+17.6% | $16.6M+25.4% | $14.5M+10.6% | $14.0M+0.7% |
| Accounts Receivable | $155.2M+45.4% | $144.4M+69.0% | $146.2M+100.1% | $115.1M+91.5% | $106.7M+145.8% | $85.4M+129.9% | $73.1M+183.1% | $60.1M+209.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $268.0M+25.5% | $270.4M+34.2% | $243.5M+27.3% | $212.9M-24.2% | $213.5M-17.4% | $201.4M-20.6% | $191.3M-24.3% | $280.7M+14.0% |
| Current Liabilities | $160.3M+54.3% | $163.2M+79.1% | $129.8M+60.3% | $99.8M-42.1% | $103.9M+102.4% | $91.1M+92.6% | $81.0M+73.6% | $172.4M+311.6% |
| Non-Current Liabilities | $107.6M-1.7% | $107.2M-2.9% | $113.7M+3.0% | $113.1M+4.5% | $109.5M-47.1% | $110.3M-46.5% | $110.3M-46.4% | $108.3M-47.0% |
| Long-Term Debt | $102.0M-4.8% | $101.5M-5.7% | $108.0M+0.7% | $107.5M+2.3% | $107.0M-47.5% | $107.6M-46.9% | $107.2M-46.9% | $105.1M-47.7% |
| Total Equity | $220.6M+58.7% | $189.6M+32.9% | $189.5M+20.3% | $158.1M+0.9% | $139.0M-25.5% | $142.7M-36.6% | $157.5M+77.7% | $156.6M+235.3% |
| Retained Earnings | -$1.1B+2.5% | -$1.1B-0.2% | -$1.1B-1.4% | -$1.2B-4.0% | -$1.2B-8.7% | -$1.1B-12.8% | -$1.1B-14.3% | -$1.1B-21.4% |
Not reported in any period shown, so not listed: Goodwill.
ARQT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12.6M+3800.9% | $2.2M+107.4% | $26.2M+3600.7% | -$1.8M+94.9% | $324K+100.7% | -$30.4M+3.9% | -$748K+98.7% | -$34.7M+21.1% |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | $3.1M+774.9% | $418K+1.0% | $1.4M-99.2% |
| Stock-Based Compensation | $12.8M+21.7% | $10.7M+9.3% | N/A | $10.0M-2.0% | $10.5M-16.2% | $9.8M-2.5% | N/A | $10.2M+2.4% |
| Capital Expenditures | $158K+102.6% | $0-100.0% | $0 | $0-100.0% | $78K | $608K | $0-100.0% | $143K+123.4% |
| Free Cash Flow | $12.5M+4973.6% | $2.2M+107.2% | $26.2M+3600.7% | -$1.8M+95.0% | $246K+100.5% | -$31.0M+1.9% | -$748K+98.7% | -$34.8M+20.9% |
| Investing Cash Flow | -$15.2M-187.4% | -$11.3M-196.4% | -$34.2M-198.0% | -$25.2M-129.8% | $17.4M+128.0% | $11.8M+140.9% | $34.9M+156.1% | $84.8M+86.1% |
| Financing Cash Flow | $2.0M+44.2% | $1.1M+170.1% | $3.7M+103.8% | $1.5M+274.6% | $1.4M-5.2% | $395K-99.8% | -$97.4M-198.1% | $394K-54.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ARQT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.6%+0.8pp | 90.7%+4.1pp | 91.0%+0.6pp | 91.3%+3.5pp | 90.8%+2.0pp | 86.6%-6.8pp | 90.3%+6.9pp | 87.7%-9.2pp |
| Operating Margin | 12.7%+30.6pp | -8.6%+28.6pp | 14.2%+24.9pp | 8.6%+95.9pp | -17.9% | -37.3%+26.5pp | -10.7% | -87.3%+9.6pp |
| Net Margin | 11.6%+31.1pp | -10.7%+27.3pp | 13.4%+28.5pp | 7.5%+100.3pp | -19.5% | -38.1%+33.3pp | -15.1% | -92.8% |
| Return on Equity | 6.8%+18.2pp | -6.0%+11.6pp | 9.2%+16.0pp | 4.7%+31.2pp | -11.4%+16.6pp | -17.6%-1.8pp | -6.8%+67.9pp | -26.5%+69.3pp |
| Return on Assets | 3.1%+7.6pp | -2.5%+4.8pp | 4.0%+7.1pp | 2.0%+11.5pp | -4.5%+7.3pp | -7.3%+0.1pp | -3.1%+16.3pp | -9.5%+5.8pp |
| Current Ratio | 2.92-0.3x | 2.68-0.9x | 3.17-1.0x | 3.50+1.0x | 3.20-5.3x | 3.55-6.3x | 4.15-2.9x | 2.46-4.3x |
| Debt-to-Equity | 0.46-0.3x | 0.54-0.2x | 0.57-0.1x | 0.680.0x | 0.77-0.3x | 0.75-0.1x | 0.68-1.6x | 0.67-3.6x |
| Asset Turnover | 0.270.0x | 0.230.0x | 0.30+0.1x | 0.27+0.2x | 0.23+0.2x | 0.19+0.1x | 0.20+0.2x | 0.100.0x |
| FCF Margin | 9.6%+9.3pp | 2.1%+49.2pp | 20.2%+21.3pp | -1.8%+76.1pp | 0.3% | -47.1%+16.7pp | -1.1% | -77.8% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. ARQT | FY2025 | $376.1M | -$16.1M | -4.3% | $3.0B | 45/100 |
| Apogee Therapeutics, Inc. APGE | FY2025 | N/A | -$255.8M | N/A | $10.2B | — |
| Tarsus Pharmaceuticals, Inc. TARS | FY2025 | $451.4M | -$66.0M | -14.6% | $3.7B | 49/100 |
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $6.2B | 70/100 |
| Agios Pharmaceuticals, Inc. AGIO | FY2025 | $54.0M | -$413.0M | N/A | $2.0B | 70/100 |
| Disc Medicine, Inc. IRON | FY2025 | N/A | -$212.2M | N/A | $2.7B | — |
Where Arcutis Biotherapeutics, Inc. Ranks
Frequently Asked Questions
What is Arcutis Biotherapeutics, Inc.'s annual revenue?
Arcutis Biotherapeutics, Inc. (ARQT) reported $376.1M in total revenue for fiscal year 2025. This represents a 91.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Arcutis Biotherapeutics, Inc.'s revenue growing?
Arcutis Biotherapeutics, Inc. (ARQT) revenue grew by 91.3% year-over-year, from $196.5M to $376.1M in fiscal year 2025.
Is Arcutis Biotherapeutics, Inc. profitable?
No, Arcutis Biotherapeutics, Inc. (ARQT) reported a net income of -$16.1M in fiscal year 2025, with a net profit margin of -4.3%.
What is Arcutis Biotherapeutics, Inc.'s EBITDA?
Arcutis Biotherapeutics, Inc. (ARQT) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Arcutis Biotherapeutics, Inc. have?
As of fiscal year 2025, Arcutis Biotherapeutics, Inc. (ARQT) had $42.9M in cash and equivalents against $108.0M in long-term debt.
What is Arcutis Biotherapeutics, Inc.'s gross margin?
Arcutis Biotherapeutics, Inc. (ARQT) had a gross margin of 90.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Arcutis Biotherapeutics, Inc.'s operating margin?
Arcutis Biotherapeutics, Inc. (ARQT) had an operating margin of -3.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Arcutis Biotherapeutics, Inc.'s net profit margin?
Arcutis Biotherapeutics, Inc. (ARQT) had a net profit margin of -4.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Arcutis Biotherapeutics, Inc.'s return on equity (ROE)?
Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity of -8.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Arcutis Biotherapeutics, Inc.'s free cash flow?
Arcutis Biotherapeutics, Inc. (ARQT) recorded an outflow of $6.3M in free cash flow during fiscal year 2025. This represents a 94.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Arcutis Biotherapeutics, Inc.'s operating cash flow?
Arcutis Biotherapeutics, Inc. (ARQT) recorded an outflow of $5.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Arcutis Biotherapeutics, Inc.'s total assets?
Arcutis Biotherapeutics, Inc. (ARQT) had $433.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Arcutis Biotherapeutics, Inc.'s capital expenditures?
Arcutis Biotherapeutics, Inc. (ARQT) invested $686K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Arcutis Biotherapeutics, Inc. spend on research and development?
Arcutis Biotherapeutics, Inc. (ARQT) invested $77.1M in research and development during fiscal year 2025.
What is Arcutis Biotherapeutics, Inc.'s current ratio?
Arcutis Biotherapeutics, Inc. (ARQT) had a current ratio of 3.17 as of fiscal year 2025, which is generally considered healthy.
What is Arcutis Biotherapeutics, Inc.'s debt-to-equity ratio?
Arcutis Biotherapeutics, Inc. (ARQT) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Arcutis Biotherapeutics, Inc.'s return on assets (ROA)?
Arcutis Biotherapeutics, Inc. (ARQT) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Arcutis Biotherapeutics, Inc.'s P/E ratio?
Arcutis Biotherapeutics, Inc. (ARQT) trades at 105x earnings, its market capitalization divided by net income of $28.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $3.0B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Arcutis Biotherapeutics, Inc.'s price-to-sales ratio?
Arcutis Biotherapeutics, Inc. (ARQT) trades at 6.5x sales, its market capitalization divided by revenue of $464.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $3.0B as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Arcutis Biotherapeutics, Inc.'s Altman Z-Score?
Arcutis Biotherapeutics, Inc. (ARQT) has an Altman Z-Score of 5.27, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Arcutis Biotherapeutics, Inc.'s Piotroski F-Score?
Arcutis Biotherapeutics, Inc. (ARQT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Arcutis Biotherapeutics, Inc.'s earnings high quality?
Arcutis Biotherapeutics, Inc. (ARQT) reported a net loss of $16.1M while operations used $5.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Arcutis Biotherapeutics, Inc. cover its interest payments?
Arcutis Biotherapeutics, Inc. (ARQT) reported an operating loss of $12.2M against $12.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Arcutis Biotherapeutics, Inc.?
Arcutis Biotherapeutics, Inc. (ARQT) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.